维莫德吉治疗基底细胞癌的聚焦：对其在治疗中地位的循证综述
Spotlight on vismodegib in the treatment of basal cell carcinoma: an evidence-based review of its place in therapy.
作者信息
Apalla Zoe, Papageorgiou Chrysoula, Lallas Aimilios, Sotiriou Elena, Lazaridou Elizabeth, Vakirlis Efstratios, Kyrgidis Athanassios, Ioannides Demetrios
机构信息
First Department of Dermatology, Aristotle University.
Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Aristotle University, Thessaloniki, Greece.
出版信息
Clin Cosmet Investig Dermatol. 2017 May 10;10:171-177. doi: 10.2147/CCID.S101330. eCollection 2017.
Abstract
Vismodegib is approved for the treatment of adult patients with metastatic (mBCC) or locally advanced basal cell carcinoma (laBCC) that have recurred following surgery or for those who are not good candidates for surgery (risk/benefit ratio is against patient's benefit, either because of the general condition or because of the expected morbidity from the surgery) or radiation therapy. This article provides an evidence-based review of its current place in therapy. Analytically, the clinical implications in the management of laBCCs and mBCCs and possible new indications, including the neoadjuvant use before surgical excision, are discussed, while in the end, the challenges regarding class-related adverse events and their optimal management are highlighted.
摘要
维莫德吉被批准用于治疗成年转移性基底细胞癌（mBCC）或局部晚期基底细胞癌（laBCC）患者，这些患者在手术后复发，或者那些不适合手术的患者（风险/获益比不利于患者，原因可能是患者的一般状况，或者是手术预期的发病率）或放射治疗。本文对其当前在治疗中的地位进行了循证综述。从分析的角度，讨论了laBCC和mBCC管理中的临床意义以及可能的新适应症，包括手术切除前的新辅助使用，最后强调了与该类药物相关的不良事件及其最佳管理方面的挑战。
相似文献
1
Spotlight on vismodegib in the treatment of basal cell carcinoma: an evidence-based review of its place in therapy.
Clin Cosmet Investig Dermatol. 2017 May 10;10:171-177. doi: 10.2147/CCID.S101330. eCollection 2017.
2
Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.
JAMA Dermatol. 2016 Jul 1;152(7):816-24. doi: 10.1001/jamadermatol.2016.0780.
3
Vismodegib: A Review in Advanced Basal Cell Carcinoma.
Drugs. 2018 Jul;78(11):1145-1156. doi: 10.1007/s40265-018-0948-9.
4
Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma.
EClinicalMedicine. 2021 Apr 26;35:100844. doi: 10.1016/j.eclinm.2021.100844. eCollection 2021 May.
5
Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc Analysis.
Dermatol Ther (Heidelb). 2021 Oct;11(5):1839-1849. doi: 10.1007/s13555-021-00588-8. Epub 2021 Sep 6.
6
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
BMC Cancer. 2017 May 16;17(1):332. doi: 10.1186/s12885-017-3286-5.
7
Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Future Oncol. 2014 May;10(6):927-36. doi: 10.2217/fon.14.50.
8
Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.
Curr Treat Options Oncol. 2019 Nov 26;20(11):84. doi: 10.1007/s11864-019-0683-9.
9
Vismodegib and Sonidegib in Locally Advanced and Metastatic Basal Cell Carcinoma: Update on Hedgehog Pathway Inhibitors.
Actas Dermosifiliogr. 2022 May;113(5):443-450. doi: 10.1016/j.ad.2022.01.005. Epub 2022 Jan 31.
10
Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia.
Dermatology. 2023;239(1):158-164. doi: 10.1159/000525612. Epub 2022 Jul 27.
引用本文的文献
1
Twelve-year continuous therapy with vismodegib for advanced basal cell carcinoma: Tolerability and partial reversibility of adverse events.
JAAD Case Rep. 2024 May 14;64:7-9. doi: 10.1016/j.jdcr.2024.05.004. eCollection 2025 Oct.
2
Itraconazole promotes melanoma cells apoptosis via inhibiting hedgehog signaling pathway-mediated autophagy.
Front Pharmacol. 2025 Jan 23;16:1545243. doi: 10.3389/fphar.2025.1545243. eCollection 2025.
3
Basosquamous Carcinoma: Comprehensive Clinical and Histopathological Aspects, Novel Imaging Tools, and Therapeutic Approaches.
Cells. 2023 Nov 30;12(23):2737. doi: 10.3390/cells12232737.
4
Non-surgical Management of Locally Advanced Basal Cell Carcinoma of the Upper Extremity With Vismodegib.
Cureus. 2022 Aug 27;14(8):e28479. doi: 10.7759/cureus.28479. eCollection 2022 Aug.
5
Basosquamous Carcinoma: A Commentary.
Cancers (Basel). 2021 Dec 6;13(23):6146. doi: 10.3390/cancers13236146.
6
Treatment of periocular basal cell carcinoma with neoadjuvant vismodegib.
Am J Ophthalmol Case Rep. 2020 May 23;19:100755. doi: 10.1016/j.ajoc.2020.100755. eCollection 2020 Sep.
7
The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer.
BioDrugs. 2020 Aug;34(4):495-503. doi: 10.1007/s40259-020-00428-9.
8
Electrochemotherapy in the treatment of locally advanced or recurrent eyelid-periocular basal cell carcinomas.
Sci Rep. 2019 Mar 12;9(1):4285. doi: 10.1038/s41598-019-41026-2.
9
Safety and Tolerability of Sonic Hedgehog Pathway Inhibitors in Cancer.
Drug Saf. 2019 Feb;42(2):263-279. doi: 10.1007/s40264-018-0777-5.
10
Sea turtle fibropapilloma tumors share genomic drivers and therapeutic vulnerabilities with human cancers.
Commun Biol. 2018 Jun 7;1:63. doi: 10.1038/s42003-018-0059-x. eCollection 2018.
本文引用的文献
1
Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial.
Lancet Oncol. 2017 Mar;18(3):404-412. doi: 10.1016/S1470-2045(17)30072-4. Epub 2017 Feb 8.
2
Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol. 2016 Dec;17(12):1720-1731. doi: 10.1016/S1470-2045(16)30566-6. Epub 2016 Nov 10.
3
Tumor regrowth and development of keratinocytic neoplasms in patients under smoothened inhibition: in vivo assessment with reflectance confocal microscopy.
Skin Res Technol. 2017 Aug;23(3):283-288. doi: 10.1111/srt.12332. Epub 2016 Oct 27.
4
Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma.
Oncotarget. 2016 Nov 15;7(46):76118-76124. doi: 10.18632/oncotarget.12660.
5
Study on the Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma: Not a Case-Control Study.
JAMA Dermatol. 2016 Oct 1;152(10):1172-1173. doi: 10.1001/jamadermatol.2016.2428.
6
Study on the Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma: Not a Case-Control Study.
JAMA Dermatol. 2016 Oct 1;152(10):1172. doi: 10.1001/jamadermatol.2016.2427.
7
Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials.
Orphanet J Rare Dis. 2016 Sep 1;11(1):120. doi: 10.1186/s13023-016-0506-z.
8
Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.
Oncologist. 2016 Oct;21(10):1218-1229. doi: 10.1634/theoncologist.2016-0186. Epub 2016 Aug 10.
9
Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC).
J Am Acad Dermatol. 2016 Jul;75(1):213-5. doi: 10.1016/j.jaad.2016.02.1235.
10
Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw. 2016 May;14(5):574-97. doi: 10.6004/jnccn.2016.0065.
Zotero 插件